Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9512-9525
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9512
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9512
Figure 3 Results of the Clarinet trial which randomized patients with enteropancreatic neuroendocrine tumors to lanreotide vs placebo.
From: Caplin et al[80]. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med 2014; 371: 224-233.
- Citation: Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525
- URL: https://www.wjgnet.com/1007-9327/full/v21/i32/9512.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i32.9512